Earnings Call · Q2 FY2021·2021-08-12

Q2 21EPS +22.73%·Rev n/aQ1 21EPS +13.64%·Rev n/aQ4 20EPS -35.29%·Rev n/aQ3 20EPS -26.67%·Rev n/a⚠ consensus missing

DiaMedica Therapeutics Inc. DMAC

Rick Pauls — Chief Executive Officer

Scott Kellen — Chief Financial Officer

−5.0%1d on move date−5.3% vs SPY3d−2.7%5d+15.7%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more DMAC calls or request research access.

More DMAC calls Browse calls Request research access